

Product Information




GPR17 (C-Term) Polyclonal Antibody

Item No. 10136 • Lot No. XXXX

- Contents:** This vial contains (100-500 µg of peptide affinity-purified IgG, *lot specific*) in 500 µl TBS, pH 7.4, containing 50% glycerol, 5 mg/ml BSA, and 0.02% sodium azide. This is sufficient antibody for at least 10 western blots.
- Synonym:** G Protein-Coupled Receptor 17
- Antigen:** Human GPR17 amino acids 351-367 (SFEGKTNESSLSAKSEL)
- Host:** Rabbit
- Cross Reactivity:** (+) Human, mouse, and rat GPR17
- Storage:** ≥1 year at -20°C
- Applications:** Flow cytometry (FC), and immunocytochemistry (ICC), western blot (WB). Recommended starting concentrations: WB - 2.5 µg/ml; FC: 10.0 µg/ml; ICC: 5-10 µg/ml; other applications were not attempted and therefore optimal working dilutions should be determined empirically.
- Concentration:** Varies by lot, from 0.2-1.0 mg/ml (100-500 µg/vial). Always 100 µl final working volume for western blotting.

GPR17 is a G protein-coupled receptor that has been identified as a dualistic receptor recognizing signals from two unrelated chemical families: nucleotides and cysteinyl leukotrienes (CysLTs).¹ The deorphanization of GPR17 supports the suggested crosstalk between nucleotides and CysLTs during inflammation and injury. mRNA transcripts encoding this transmembrane receptor are most strongly expressed in the brain, kidney, and heart. Upon ischemic injury, GPR17 is upregulated in these tissues and its inhibition has been shown to decrease ischemic damage. This finding suggests GPR17 as a pharmacological target of ischemic injury.¹ Cayman's peptide affinity-purified polyclonal antibody recognizes the C-terminal region of human GPR17. This protein exists in two isoforms, differing by 28 amino acids at the receptor N-terminus. The longer form of the protein consists of 367 amino acids with a calculated molecular weight of 41 kDa. The human and rat proteins share 89% amino acid identity.¹ Post-translational modifications may explain the observed SDS-PAGE gel-migration to 57 kDa on immunoblot.



Lane 1: C6 (mouse) cell lysate (30 µg)
Lane 2: HUVEC cell lysate (30 µg)
Lane 3: HL60 cell lysate (25 µg)

Reference

1. Ciana, P., Fumagalli, M., Trincavelli, M.L., *et al.* The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. *EMBO J.* **25**, 4615-4627 (2006).

Related Products

For a list of related products please visit: www.caymanchem.com/catalog/10136

Cayman Chemical

Mailing address
1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone
(800) 364-9897
(734) 971-3335

Fax
(734) 971-3640

E-Mail
custserv@caymanchem.com

Web
www.caymanchem.com

WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY. NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

MATERIAL SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Material Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman **warrants only** to the original customer that the material will **meet our specifications at the time of delivery.**

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have **any obligation or liability**, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's **exclusive remedy** and Cayman's sole liability hereunder shall be limited to a **refund** of the purchase price, or at Cayman's option, the **replacement**, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our **Warranty and Limitation of Remedy** located on our website and in our catalog.

Copyright Cayman Chemical Company, 02/03/2012